British Journal of Dermatology

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

BACKGROUND: Facial repigmentation is the primary outcome measure for most vitiligo trials. The Facial Vitiligo Area Scoring Index (F-VASI) score is often chosen as the primary outcome measure to assess the efficacy of treatments for facial vitiligo. Although useful, this scoring system remains subjective and has several limitations. OBJECTIVES: To assess agreement and reliability of an algorithmic method to measure percent depigmentation of vitiligo on the face...

BACKGROUND: Lymphatic Filariasis (LF) is a neglected tropical disease presenting mainly as lymphoedema (elephantiasis). LF is not effectively treated. Integrative Medicine treatment (IM) for lymphoedema uses a combination of Indian traditional medicine, ayurveda, alongside yoga exercises, compression therapy, antibiotics and antifungals, providing a useful combination where resources are limited and different practices are in use. OBJECTIVES: To assess the effectiveness of the IM in the existing clinical practice of lower limb lymphoedema management and to determine whether the treatment outcomes aligned with the WHO's global goal of LF...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

Resident memory T-cells (T-RMs) remain in epithelial barrier tissues after antigen exposure and the initial effector phase. These T-RMs provide effective antimicrobial and anticancer immunity, however pathogenic T-RMs have been shown to mediate various chronic inflammatory disorders in a variety of tissue types. In the skin, T-RMs are referred to as resident cutaneous memory T-cells (cT-RMs). Understanding the mechanisms leading to the development and establishment of these cT-RMs populations may allow for targeted treatments providing durable responses in chronic immune-mediated skin diseases, even after cessation...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

No abstract text is available yet for this article.

BACKGROUND: People with a previous melanoma are at increased risk of developing another primary melanoma when compared with the general population. Understanding risk factors associated with multiple primary melanomas can inform patient education and tailored surveillance. OBJECTIVES: We conducted a systematic review and meta-analysis to examine risk factors for subsequent primary melanoma. METHODS: A systematic literature search was conducted on CINAHL, Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE and MEDLINE...

BACKGROUND: Sleep disturbance is a prominent symptom of atopic dermatitis (AD) and can result in insomnia, daytime fatigue, drowsiness, reduced productivity, and impaired quality of life (QoL). OBJECTIVES: The DUPISTAD (Dupilumab Effect on Sleep in AD Patients) phase 4 randomized double-blinded placebo-controlled study evaluated the impact of dupilumab treatment on sleep and other patient- and physician-reported outcomes. METHODS: Adults with moderate-to-severe AD were randomized 2:1 to dupilumab 300 mg once every 2 weeks (q2w) or placebo for 12 weeks; concomitant topical corticosteroids were permitted...

No abstract text is available yet for this article.

BACKGROUND: Core outcome sets (COS) are consensus-driven sets of minimum outcomes that should be measured and reported in all clinical trials. COS aim to reduce heterogeneity in outcome measurement and reporting, and selective outcome reporting. Implementing COS into clinical trials is challenging. Guidance to improve COS uptake in dermatology is lacking. OBJECTIVE: To develop a structured practical guide to COS implementation. METHODS: Members of the Harmonising Outcome Measurement for Eczema (HOME) executive committee developed an expert-opinion based roadmap founded on a combination of a review of COS implementation literature, the Core Outcome Measures in Effectiveness Trials (COMET) initiative resources, input from HOME members, and experience in COS development and clinical trials...

BACKGROUND: Hidradenitis suppurativa significantly diminishes the quality of life for patients. Delayed diagnosis represents a significant challenge in effectively managing hidradenitis suppurativa. OBJECTIVES: To identify and characterize the key mediator in hidradenitis suppurativa. METHODS: Bioinformatic analysis of transcriptomic was applied to identify potential candidates contributing to the disease process of hidradenitis suppurativa...